BR112023022319A2 - Anticorpos anti-tigit, anticorpos anti-cd96 e métodos de uso dos mesmos - Google Patents

Anticorpos anti-tigit, anticorpos anti-cd96 e métodos de uso dos mesmos

Info

Publication number
BR112023022319A2
BR112023022319A2 BR112023022319A BR112023022319A BR112023022319A2 BR 112023022319 A2 BR112023022319 A2 BR 112023022319A2 BR 112023022319 A BR112023022319 A BR 112023022319A BR 112023022319 A BR112023022319 A BR 112023022319A BR 112023022319 A2 BR112023022319 A2 BR 112023022319A2
Authority
BR
Brazil
Prior art keywords
antibodies
tigit
methods
multispecific molecules
human
Prior art date
Application number
BR112023022319A
Other languages
English (en)
Inventor
Maxime Morin Benjamin
Beth Wensley
Sidhartha Chand Dhan
Cyrille Pascal Briend Emmanuel
Mark Bushell K
Anne Ramsay Nicola
Olga Ignatovich
Spencer Campbell
Franciszka Ilkow Veronica
Zahra Jawad
Original Assignee
Agenus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc filed Critical Agenus Inc
Publication of BR112023022319A2 publication Critical patent/BR112023022319A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

anticorpos anti-tigit, anticorpos anti-cd96 e métodos de uso dos mesmos. a presente invenção refere-se moléculas multiespecíficas que se ligam especificamente a cd96 (por exemplo, cd96 humana) e/ou tigit (por exemplo, tigit humano) e anticorpos isolados que se ligam especificamente a tigit (por exemplo, tigit humano). também são fornecidas composições farmacêuticas compreendendo essas moléculas multiespecíficas e anticorpos, ácidos nucleicos que codificam essas moléculas multiespecíficas e anticorpos, vetores de expressão e células hospedeiras para produzir essas moléculas multiespecíficas e anticorpos, e métodos de tratamento de um indivíduo usando essas moléculas multiespecíficas e anticorpos.
BR112023022319A 2021-05-04 2022-05-04 Anticorpos anti-tigit, anticorpos anti-cd96 e métodos de uso dos mesmos BR112023022319A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163201537P 2021-05-04 2021-05-04
PCT/US2022/072099 WO2022236276A2 (en) 2021-05-04 2022-05-04 Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112023022319A2 true BR112023022319A2 (pt) 2024-02-20

Family

ID=83933041

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022319A BR112023022319A2 (pt) 2021-05-04 2022-05-04 Anticorpos anti-tigit, anticorpos anti-cd96 e métodos de uso dos mesmos

Country Status (14)

Country Link
US (2) US11718669B2 (pt)
EP (1) EP4333893A2 (pt)
JP (1) JP2024516843A (pt)
KR (1) KR20240006054A (pt)
CN (1) CN117425494A (pt)
AR (1) AR125753A1 (pt)
AU (1) AU2022271331A1 (pt)
BR (1) BR112023022319A2 (pt)
CA (1) CA3217289A1 (pt)
CO (1) CO2023016037A2 (pt)
IL (1) IL308157A (pt)
PE (1) PE20240369A1 (pt)
TW (1) TW202304965A (pt)
WO (1) WO2022236276A2 (pt)

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121370A1 (en) 2002-09-11 2004-06-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
EP2397493A1 (en) 2005-05-12 2011-12-21 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
CA2719189C (en) 2008-04-09 2020-08-04 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
IL300733A (en) 2010-03-05 2023-04-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeting immune modulation
US20130287797A1 (en) 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
US9212227B2 (en) * 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
EP2858673A4 (en) 2012-06-06 2016-06-22 Oncomed Pharm Inc BINDING AGENTS MODULATING THE HIPPO SIGNALING PATH AND USES THEREOF
PL3021869T3 (pl) 2013-07-16 2020-11-16 F. Hoffmann-La Roche Ag Sposoby leczenia nowotworu z użyciem antagonistów wiązania osi PD-1 i inhibitorów TIGIT
US20160208000A1 (en) 2013-08-22 2016-07-21 The Council Of The Queensland Institute Of Medical Research Immunoreceptor modulation for treating cancer and viral infections
US10966998B2 (en) 2013-09-05 2021-04-06 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
CN105765063B (zh) * 2013-09-30 2021-05-07 中外制药株式会社 应用改变的辅助噬菌体制备抗原结合分子的方法
CN106687125B (zh) 2014-03-12 2021-12-14 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
EP3119913B1 (en) 2014-03-21 2021-01-06 The Brigham and Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
AU2015260230A1 (en) 2014-05-13 2016-11-17 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
CN112546231A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
PE20170140A1 (es) 2014-07-16 2017-03-30 Genentech Inc Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
TN2017000024A1 (en) 2014-08-19 2018-07-04 Merck Sharp & Dohme Anti-tigit antibodies.
PE20171067A1 (es) 2014-10-14 2017-07-24 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
CA3003133C (en) 2014-10-24 2020-09-15 StemImmune, Incorporated Combination immunotherapy approach for treatment of cancer
SG11201703376QA (en) 2014-11-06 2017-05-30 Genentech Inc Combination therapy comprising ox40 binding agonists and tigit inhibitors
TN2017000267A1 (en) 2014-12-23 2018-10-19 Bristol Myers Squibb Co Antibodies to tigit
BR112017020491A2 (pt) 2015-03-25 2018-07-17 The Regents Of The University Of Michigan composições e métodos para distribuição de agentes de biomacromolécula.
WO2016180781A1 (en) 2015-05-08 2016-11-17 Michele Maio Combination therapy of mesothelioma
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
EP3328363A4 (en) 2015-07-31 2019-08-21 Tarveda Therapeutics, Inc. COMPOSITIONS AND METHODS OF IMMUNOMODULATION
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
JP6976241B2 (ja) 2015-08-14 2021-12-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗ｔｉｇｉｔ抗体
EP3344656A1 (en) 2015-09-01 2018-07-11 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
ES2924071T3 (es) 2015-09-02 2022-10-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos específicos para inmunoglobulina de células T humanas y dominio ITIM (TIGIT)
EP3349792A1 (en) 2015-09-14 2018-07-25 Compass Therapeutics LLC Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-
CN113956358A (zh) 2015-09-25 2022-01-21 豪夫迈·罗氏有限公司 抗tigit抗体和使用方法
WO2017059095A1 (en) 2015-10-01 2017-04-06 Potenza Therapeutics, Inc. Anti-tigit antigen-binding proteins and methods of use thereof
EP3359192A4 (en) 2015-10-08 2019-05-01 MacroGenics, Inc. POLY THERAPY FOR THE TREATMENT OF CANCER
AU2016335848B2 (en) 2015-10-09 2020-12-17 Miltenyi Biotec Technology, Inc. Chimeric antigen receptors and methods of use
KR20180108655A (ko) 2016-01-15 2018-10-04 알에프이엠비 홀딩스, 엘엘씨 암의 면역학적 치료
WO2017152088A1 (en) 2016-03-04 2017-09-08 JN Biosciences, LLC Antibodies to tigit
US20170360932A1 (en) 2016-06-17 2017-12-21 Varian Medical Systems, Inc. Immune modulators in combination with radiation treatment
EP3471778A4 (en) 2016-06-20 2020-02-19 The Regents of The University of Michigan COMPOSITIONS AND METHOD FOR DELIVERING BIOMACROMOLECOLIC ACTIVE SUBSTANCES
MY194032A (en) 2016-08-17 2022-11-09 Compugen Ltd Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
JP7200093B2 (ja) 2016-09-15 2023-01-06 アイデラ・ファーマシューティカルズ，インコーポレーテッド がん治療用ｔｌｒ９アゴニストを用いた免疫調節
CN110662552A (zh) 2016-11-30 2020-01-07 昂科梅德制药有限公司 包含tigit结合剂的癌症治疗方法
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
CN109071656B (zh) 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
SG11201907278VA (en) 2017-02-28 2019-09-27 Seattle Genetics Inc Anti-tigit antibodies
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
ES2952961T3 (es) 2017-05-01 2023-11-07 Agenus Inc Anticuerpos anti-TIGIT y métodos de uso de los mismos
MX2019013033A (es) 2017-05-02 2020-02-05 Merck Sharp & Dohme Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso.
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
SG11202000660QA (en) 2017-07-27 2020-02-27 Iteos Therapeutics Sa Anti-tigit antibodies
TWI803523B (zh) 2017-09-29 2023-06-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｔｉｇｉｔ抗體、其抗原結合片段及醫藥用途
US20200347130A1 (en) 2017-11-10 2020-11-05 Jiangsu Hengrui Medicine Co., Ltd. CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
CN111699198B (zh) 2017-12-28 2023-09-05 南京传奇生物科技有限公司 针对tigit的单域抗体和其变体
TWI816729B (zh) * 2017-12-30 2023-10-01 英屬開曼群島商百濟神州有限公司 抗tigit抗體及其作為治療和診斷的用途
TW201932489A (zh) 2018-01-15 2019-08-16 大陸商南京傳奇生物科技有限公司 針對ｔｉｇｉｔ之抗體及其變異體
WO2019152574A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody
US10973853B2 (en) 2018-02-06 2021-04-13 I-Mab Biopharma Us Limited Antibodies to T cell immunoreceptor with IG and ITIM domains (TIGIT) and uses thereof
AU2019225249A1 (en) 2018-02-26 2020-09-17 Genentech, Inc. Dosing for treatment with anti-tigit and anti-PD-L1 antagonist antibodies
MX2020008795A (es) 2018-02-28 2020-10-08 Yuhan Corp Anti cuerpos anti tigit y usos de los mismos.
EA202191176A1 (ru) * 2018-10-31 2021-07-28 Делиниа, Инк. Поливалентные модуляторы регуляторных т-клеток
EP3938396A1 (en) * 2019-03-11 2022-01-19 Jounce Therapeutics, Inc. Anti-icos antibodies for the treatment of cancer
WO2020263879A1 (en) * 2019-06-26 2020-12-30 Ap Biosciences, Inc. Antibodies for t-cell activation
CN114585644A (zh) 2019-08-30 2022-06-03 艾吉纳斯公司 抗cd96抗体及其使用方法
EP4333894A1 (en) * 2021-05-04 2024-03-13 Agenus Inc. Anti-tigit antibodies and methods of use thereof

Also Published As

Publication number Publication date
AU2022271331A1 (en) 2023-10-26
US11718669B2 (en) 2023-08-08
AU2022271331A9 (en) 2023-11-09
TW202304965A (zh) 2023-02-01
CN117425494A (zh) 2024-01-19
KR20240006054A (ko) 2024-01-12
CA3217289A1 (en) 2022-11-10
IL308157A (en) 2024-01-01
PE20240369A1 (es) 2024-03-04
CO2023016037A2 (es) 2023-11-30
WO2022236276A2 (en) 2022-11-10
US20240141039A1 (en) 2024-05-02
JP2024516843A (ja) 2024-04-17
US20230014036A1 (en) 2023-01-19
EP4333893A2 (en) 2024-03-13
WO2022236276A3 (en) 2023-01-19
AR125753A1 (es) 2023-08-09

Similar Documents

Publication Publication Date Title
BR112022014667A2 (pt) Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
BR112018072485A2 (pt) proteínas de ligação biespecíficas e usos das mesmas
BR112019010265A2 (pt) anticorpos anti_cd137 inovadores e usos dos mesmos
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
BR112018006547A2 (pt) anticorpos de pd-1 e usos dos mesmos
BR112018007046A2 (pt) anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, molécula de polinucleotídeo isolado, vetor, célula, e, métodos para inibir o crescimento de um tumor ou de uma célula tumoral e para tratar uma doença ou distúrbio.
BR112022013236A2 (pt) Anticorpos anti-cd73 e usos dos mesmos
BR112022003740A2 (pt) Anticorpos anti-cd96 e métodos de uso dos mesmos
BR112017010110A2 (pt) anticorpos contra cd73 e usos do mesmo
BR112022001460A2 (pt) Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
BR112019008634A2 (pt) anticorpos anti-pd-l1 e variantes
BR112016013347A8 (pt) anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos.
EA202092735A1 (ru) Антагонизирующее cd73 антитело
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
BR112019005316A2 (pt) anticorpos monoclonais para morte programada 1 (pd-1)
BR112022004047A2 (pt) Proteínas de ligação multiespecíficas para o tratamento de câncer
BR112019005129A2 (pt) anticorpos anti-pd-1
EA201990321A1 (ru) Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123
BR112022000216A2 (pt) Anticorpos direcionados a dll3 e usos dos mesmos
BR112017027702A2 (pt) anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2)
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
BR112021018608A2 (pt) Anticorpos para claudina-6 e conjugados de fármaco